Taysha Gene Therapies (TSHA) PT Raised to $43 at Morgan Stanley
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Price: $4.63 -2.32%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $43.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- JPMorgan Downgrades Singapore Exchange (SGX:FP) (SPXCY) to Neutral
- JPMorgan Upgrades Sandfire Resources NL (SFR:AU) (SNDFY) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
